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Objectives: This study was designed to investigate whether transmyocardial laser
revascularization induces myocardial denervation and to correlate this with myo-
cardial perfusion and clinical status.
Methods: Transmyocardial laser revascularization was performed with a Holmium:
YAG (n  3) or xenon chloride excimer laser (n  5). Preoperative and postop-
erative iodine 123–labeled meta-iodobenzylguanide SPECT scintigraphy to assess
cardiac innervation and perfusion scintigraphy were also performed. Furthermore, New
York Heart Association functional angina class and quality of life were assessed.
Results: In all patients postoperative iodine 123–labeled meta-iodobenzylguanide
SPECT showed significantly decreased uptake and therefore sympathetic myocar-
dial denervation at up to 16 months’ follow-up (average preoperative and postop-
erative summed defect scores of 14.8  5.3 and 24.5  4.2, respectively; P 
.00005). In 86% of segments, the decreased meta-iodobenzylguanide uptake could
be correlated to the treated area. In all patients angina was reduced by 2 or more
classes at 12 months’ follow-up, and quality of life improved significantly.
Conclusions: Transmyocardial laser revascularization–induced improvement of an-
gina and quality of life can be explained by destruction of nociceptors or cardiac
neural pathways, changing the perception of anginal pain.
Transmyocardial laser revascularization (TMLR) is a therapy forsevere angina pectoris refractory to antianginal medication, percu-taneous transluminal coronary angioplasty, and coronary artery by-pass grafting. At low operative risk, CO2 and Holmium:YAG TMLRrelieve angina pectoris1-5 and improve quality of life (QOL)1-3,6 andexercise time.1,2,4,5 Furthermore, nonrandomized xenon chloride
(XeCl) excimer TMLR achieves similar anginal relief.7,8 However, the angina-
relieving mechanism is still poorly understood and probably multifactorial, reducing
acceptance of TMLR. The original idea that direct perfusion from the left ventricle
through the laser channels improves myocardial perfusion9 currently has little
support.10 Other hypotheses are TMLR-induced stimulation of angiogenesis11 or
destruction of cardiac nociceptors and afferent nerve fibers,12 which is investigated
in the study reported here. Only one other clinical study has reported sympathetic
myocardial denervation after Holmium:YAG TMLR.13 However, in that study 2 of
8 patients postoperatively showed increased myocardial innervation, and 5 had
diabetes mellitus, introducing possible interference through diabetic neuropathy.
Furthermore, denervation location was not correlated with the treated area.
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In the present study we divided the heart in segments and
related changes in sympathetic innervation with treated
area, perfusion, and clinical performance in patients treated
with Holmium:YAG or excimer TMLR. We excluded con-
founding factors, such as preoperative myocardial infarction
and diabetes mellitus, in all but one patient.
Methods
Study Design
Patients were recruited from a randomized clinical trial (RCT)
investigating the clinical efficacy of Holmium:YAG and XeCl
excimer TMLR. Inclusion criteria were angina pectoris of New
York Heart Association functional class III-IV/IV (not eligible for
percutaneous transluminal coronary angioplasty or coronary artery
bypass grafting as determined by an experienced cardiac surgeon
and interventional cardiologist at the trial center), a scintigraphi-
cally proved reversible perfusion defect, a left ventricular ejection
fraction of 35% or greater, and a life expectancy of greater than 1
year. Exclusion criteria were ventricular arrhythmias requiring
treatment, clinically manifest heart failure, severe intrinsic hem-
orrhagic disorders, and lack of informed consent.
Between March 1998 and June 2001, 30 of 118 patients
screened for TMLR were included in the RCT, of which 8 were
included in the study reported here. All other RCT patients were
excluded either because of diabetic neuropathy or because of
previously documented myocardial infarction (maximal CK-MB
of 25 g/L) because denervation and regeneration of neural
tissue occurs in varying degrees in viable myocardium adjacent to
infarcted myocardium. Iodine 123–labeled meta-iodobenzylgua-
nide (123I-MIBG) SPECT scintigraphy was performed at baseline
and postoperatively at 1 (n  5), 4 (n  1), 9 (n  1), or 16 (n 
1) months’ follow-up. Myocardial perfusion was evaluated by
means of technetium 99m–labeled tetrofosmin (99mTc-TF) SPECT
scintigraphy at baseline (at 3 months  3 weeks before TMLR)
and at 3 and 12 months’ follow-up. Angina class, QOL, and
exercise time were assessed at baseline and at 3, 6, and 12 months.
The in-hospital medical ethical committee approved the study, and
all patients provided written informed consent. The funding
agency played no role in data interpretation.
Angina Class, QOL, and Exercise Time
Angina class was assessed by one investigator (JAPvdS); QOL
was assessed by using the Seattle Angina Questionnaire (SAQ)14
and the EuroQol Standardized Questionnaire’s Visual Analog
Scale (VAS),15 which ranges from 0% (worst imaginable health)
to 100% (best imaginable health). Exercise time was assessed by
using a modified Bruce protocol.
Myocardial Perfusion Scintigraphy
Myocardial perfusion scintigraphy was performed according to the
guidelines of the American Society of Nuclear Cardiology16 by
using 99mTc-TF and a 2-day stress-rest protocol. Stress was in-
duced by means of exercise (bicycle ergometry) or, if exercise was
contraindicated or suboptimal, pharmacologically (0.14 mg · kg1
· min1 adenosine for 6 minutes). For each individual patient, the
stress modality used at baseline was also used at follow-up.
All patients fasted for 4 hours before perfusion scintigraphy.
99mTc-TF (approximately 500 MBq; Nycomed Amersham, Buck-
inghamshire, United Kingdom) was injected at maximal exercise
or after 4 minutes of pharmacologic stress and also at rest. SPECT
was performed 1 hour after 99mTc-TF injection. Images were
obtained with the patient in the prone position by using a 3-headed
gamma camera (MultiSPECT-3; Siemens, Hoffman Estate, Ill)
with low-energy and high-resolution collimators, a 20% energy
window centered on the 99mTc 140-keV photopeak, 20 views per
camera head, and 45 seconds per view in a 64  64 matrix by
using the camera autocontour facility and standard filtered back
projection without applying attenuation correction. Short-axis
slices were obtained and used for a segmental bull’s-eye recon-
struction. Stress and rest images were scored by using a validated
and widely used 3-dimensional sampling and analysis algorithm,
which generates a 5-point 99mTc-TF uptake score (a measure for
myocardial perfusion) for each myocardial segment.17 Uptake was
classified as normal (0), equivocal abnormal (1), mildly abnormal
(2), moderately abnormal (3), or severely abnormal (4). With this
classification, the algorithm used the stress and rest scans to
calculate (per patient) a summed stress score, a summed rest score
(SRS), and a summed difference score (SDS), which is generated
from the summed stress score and SRS. Because the 2 basal-septal
segments represent the membranous part of the septum, they were
excluded from the SDS, leaving the sum of 18 segments. This
18-segment SDS was used in further analyses. The nuclear med-
icine physicians (HJV and BLFvE-S), blinded to treated area and
123I-MIBG SPECT, reviewed the generated scores per segment. In
case of artifact scoring by the algorithm program, scores were
manually adjusted.
123I-MIBG SPECT
MIBG and noradrenaline have similar molecular structures, and
both use the same uptake and storage mechanisms in sympathetic
nerve endings.18 123I labeling of MIBG enables scintigraphic vi-
sualization of the cardiac sympathetic nervous system, and uptake
is therefore a measure of innervation. Because -blocker therapy
affects MIBG uptake, it is noteworthy that the dosage of -block-
ers of each individual patient at preoperative MIBG scintigraphy
was identical to that at postoperative MIBG scintigraphy.
All patients received a single oral dose of 100 mg of potassium
iodine to block thyroid uptake of free radioactive iodine 1 hour
before administration of the radiopharmaceutical. SPECT was
performed 4 hours after intravenous administration of 185 MBq of
123I-MIBG (Nycomed Amersham), as described above for
99mTc-TF SPECT, by using medium-energy collimators, an energy
window centered on the 123I 159-keV photopeak, and 60 seconds
per view. Data reconstruction was performed with a Wiener filter.
Short-axis slices were obtained and used to construct the same
segmental bull’s-eye, as described above. The fully automatic
border-detection feature of a 3-dimensional sampling and analysis
algorithm17 was used to delineate myocardial borders. Despite
MIBG uptake in the lungs and liver, in only 1 of 16 scans was
manual correction of the automatic delineation required (per-
formed by the 2 nuclear medicine specialists), and therefore in 15
123I-MIBG SPECT scans the automatic delineation was successful.
The program described above could not be used for the 123I-
MIBG SPECT analysis because it is not validated for 123I-MIBG
SPECT. Therefore 123I-MIBG SPECT results before and after
TMLR were visually analyzed by the 2 nuclear medicine physi-
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cians, who were blinded to treated area and perfusion scintigraphy.
However, for each segment, an identical 5-point scoring system
was used for MIBG uptake: normal (0), equivocal abnormal (1),
mildly abnormal (2), moderately abnormal (3), or severely abnor-
mal (4). For each patient, a preoperative summed score, a postop-
erative summed score, and a summed myocardial denervation
score, defined as the postoperative summed score minus the pre-
operative summed score, was calculated for 18 segments.
Operative Technique and TMLR Procedure
A left lateral thoracotomy was performed in the fifth or sixth
intercostal space, and TMLR was performed in the ischemic area
of the left ventricular wall as preoperatively assessed by means of
perfusion scintigraphy. Approximately 1 channel per square cen-
timeter was created with excimer TMLR, and 1 channel per 1.5
cm2 was created with Holmium:YAG TMLR. Transmyocardial pen-
etration was confirmed by using transesophageal echocardiography.
The Holmium:YAG laser (NSLX-6; CardioGenesis Corp,
Sunnyvale, Calif; wavelength of 2.1 m, 2.0 J per pulse, pulse
duration of 350 s, 19 Hz) was used with a 1.9-mm diameter
spherically tipped fiber and its own trigger device. The myocar-
dium was perforated by gently and manually advancing the fiber
during 2 to 3 triggered cardiac cycles (3 pulses per cycle). With the
XeCl excimer laser (Max-20; Medolas, Munich, Germany; 308
nm, 37-40 mJ per pulse, 110 ns, 40 Hz), which was combined with
a hospital-built electrocardiographic trigger device, the myocar-
dium was perforated by gently and manually advancing a 1-mm-
diameter flat-tipped fiber during 3 to 4 triggered cardiac cycles
(4-5 pulses per cycle).
Basal-septal and midseptal segments were not treated to pre-
vent damage to the bundle branches. Apicoseptal segments were
sometimes treated through the apex. Immediately after the proce-
dure, the surgeon recorded the treated segments by drawing them
into a bull’s-eye presentation of the heart. Postoperative care was
identical to that after cardiac surgery. Preoperative antianginal
medication was resumed on the first postoperative day. Myocardial
damage was assessed on the basis of maximal CK-MB.
Statistical Analysis
Student t tests (all paired and 2 tailed) were used for statistical
analyses of preoperative and postoperative angina class, QOL,
exercise time, myocardial perfusion scintigraphy (SDS), and 123I-
MIBG SPECT scintigraphy (summed scores). Results are given as
means  SD.
Results
Tables 1 and 2 summarize preoperative, perioperative, and
postoperative patient characteristics. Deliberately, the num-
ber of Holmium:YAG laser channels was lower than with
the excimer laser because at the laser settings used, 1.9-mm
Holmium:YAG fibers induce more mechanical and thermal
Figure 1. Results of the Seattle Angina Questionnaire (SAQ) and EuroQol Questionnaire’s visual analogue scale
(VAS). *VAS and all SAQ domains; †VAS and SAQ domains with exception of treatment satisfaction.
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injury than 1-mm excimer fibers. The average in-hospital
stay was 9 days for both the Holmium:YAG and excimer
TMLR groups. None of the patients died during follow-up.
Angina Class, QOL, and Exercise Time
Angina improved by 2 or more classes (New York Heart
Association) in 7 of 8 patients at 3 months’ follow-up and in
all 8 patients at 12 months’ follow-up (Table 2). Overall,
QOL (Figure 1) was significantly improved at 3 months’
follow-up in all 5 domains of the SAQ and in the VAS.
These improvements were still significant at 12 months’
follow-up with the exception of the treatment satisfaction
domain of the SAQ. No differences were seen between
patients undergoing treatment with the Holmium:YAG and
excimer lasers. Overall, TMLR did not improve exercise
time (526  201 seconds preoperative vs 558  217 and
549  222 seconds at 3 and 12 months).
Myocardial Segments Treated With TMLR
Of 144 segments (8 patients, 18 segments per patient), 74
were treated with TMLR (range, 6-14 segments per patient).
Furthermore, 63 of 144 segments demonstrated a reversible
perfusion defect preoperatively; 58 of these were eligible
for TMLR (the other 5 were midseptal segments), and 46
(79%) of these 58 segments were actually treated with
TMLR. Consequently, 46 (62%) of 74 treated segments
preoperatively showed a reversible perfusion defect. Of the
remaining 28 treated segments, 7 showed a minimal rest
score (of 1 or 2), and the remaining 21 showed no defects.
Figure 2 summarizes the results.
123I-MIBG SPECT and Myocardial Perfusion
Scintigraphy
Table 3 summarizes the scintigraphic results. Preopera-
tively, 27 of 62 segments with a decreased MIBG uptake
corresponded with areas at risk on perfusion scintigraphy.
All patients had a positive summed myocardial denervation
score, and MIBG uptake decreased after TMLR in 45% of
treated segments (Figure 2). If we assume that there was no
significant difference in the maximum preoperative and
postoperative MIBG uptake (that in each individual was in
a nontreated basal segment and preoperatively was at the
same cardiac location as postoperatively), we can conclude
that none of the 144 segments showed increased innerva-
TABLE 1. Preoperative patient characteristics
Patient no. Sex Age (y)
Previous
CABG
Previous
PTCA LVEF (%) DM Cardiac medication
1 M 61   56  -b/Ca/Ni
2 M 51   53  -b/Ca
3 M 53   61  -b/Ni
4 M 60   50  -b/Ca/Ni
5 F 57   58  -b/Ca/Ni
6 M 48   61  -b/Ca/Ni
7 M 59   60  -b/Ca/Ni
8 M 60   55  -b/Ca/Ni
CABG, Coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; LVEF, left ventricular ejection fraction; DM, diabetes
mellitus; -b, beta-blocker; Ca, calcium antagonist; Ni, long-acting nitrate.
TABLE 2. Perioperative and postoperative patient characteristics
Patient no. Laser
No. of
channels
CK-MBmax
(g/L)
NYHA
preoperative
NYHA 3 mo
follow-up
NYHA 12 mo
follow-up
1 Excimer 64 23 3 2 1
2 Holmium:YAG 43 36 4 2 2
3 Excimer 59 101† 4 2 2
4 Excimer 50 43 4 2 2
5 Holmium:YAG 27 28 4 2 2
6 Excimer 50 29 4 2 2
7 Holmium:YAG 23 18 4 1 2
8 Excimer 42 25 4 1 2
Mean SD Excimer: 53 9 44 33 3.8 0.5 1.8 0.5* 1.6 0.6*
Holmium:YAG 31 11 27 9 4.0 0 1.7 0.6* 2.0 0*
*P  .05 compared with preoperative value.
†Because of a small subendocardial infarction that neither affected wall motion nor 123I-MIBG scintigraphy value.
NYHA, Angina class according to the classification of the New York Heart Association.
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tion. Overall, in 50 segments MIBG uptake was decreased
after TMLR, and 33 (66%) of these had been treated. No
significant differences in MIBG uptake were found between
Holmium:YAG and excimer TMLR. On average, perfusion
remained unchanged at 3 and 12 months. No postoperative
increase in scar size was observed (average SRS was 4.4 
5.2 at baseline vs 6.1  5.0 at 3 months [P  .2] and 4.1 
4.6 at 12 months). Figure 3 shows a patient example.
Discussion
Our results support previous evidence that denervation
plays a role in anginal relief after TMLR.13 To our knowl-
edge, this is the first segmental analysis of innervation
correlated to perfusion and TMLR-treated area. Also, be-
cause no patient had diabetic neuropathy (because only one
diabetic was included with no signs of neuropathy), the
possible interference of diabetic neuropathy with the studied
denervation effects is minimized.
Denervation Hypothesis
The denervation hypothesis originates from the observation
that TMLR can relieve angina within days. Because func-
tional angiogenesis is unlikely to occur within days, anginal
relief through direct intervention in (neural) pain sensation
by means of cardiac denervation is thought to play a role.
Anginal perception is believed to be transported to the brain
through cardiac nociceptors and afferent fibers.19 The latter
are located superficially in the epicardium20 and thus are
easily accessible by means of TMLR. Other indications that
interference in neural pathways can contribute to anginal
relief are the beneficial effects on angina of neuromodulat-
ing therapies, such as spinal cord stimulation and thoracic
epidural anesthesia.21,22 Also, diabetics frequently experi-
ence silent ischemia (without anginal complaints) because
diabetic neuropathy often destroys sympathetic myocardial
fibers.23 Moreover, patients lack angina after heart trans-
plantation, despite development of extensive coronary ar-
tery disease.
Experimental Evidence
Experimental myocardial denervation studies after TMLR
show conflicting results.10 In a canine model Kwong and
colleagues12 reported that Holmium:YAG TMLR destroys
cardiac nerve fibers, as assessed on the basis of cardiac
afferent nerve function (epicardial bradykinin) and tyrosine
hydroxylase measurements 2 weeks postoperatively. Using
the same assessment and follow-up, Yamamoto and associ-
ates24 reported radiofrequency TMR-associated denervation
in canines comparable with that after TMLR. In contrast,
Minisi and coworkers25 and Hirsch and colleagues26 re-
ported no effect of Holmium:YAG TMLR in canines by
using various acute neural assessments. However, Arora
and associates27 also studied TMLR effects (after 4 weeks),
and they concluded that remodeling of the intrinsic cardiac
nervous system might account, at least in part, for delayed
symptomatic benefits in patients undergoing TMLR. Fi-
nally, one study, using the same assessment techniques as
described in the clinical study reported here (MIBG
SPECT) in a 3-day survival porcine model, has reported a
negligible effect of endocardial Holmium:YAG channels
(percutaneous myocardial revascularization [PMR]) on de-
nervation.28 This might be explained by the epicardial lo-
cation of the sympathetic fibers (less damaged by PMR) and
because PMR affects myocardium to a lesser extent. These
differences might also explain the reported difference in
clinical efficacy between TMLR and PMR.29
Clinical Evidence
Al-Sheikh and coworkers13 have investigated sympathetic
innervation and myocardial ischemia with positron emission
tomography imaging by using 11C-hydroxyephedrine and
13N-ammonia, respectively. In 8 patients undergoing Hol-
mium:YAG, positron emission tomographic imaging was
performed at baseline and 2 months postoperatively. All
patients experienced improvement of 2 or more angina
classes. As in our study, TMLR did not significantly affect
myocardial perfusion. 11C-hydroxyephedrine measurements
showed decreased innervation after TMLR in 6 of 8 patients
and, surprisingly, increased innervation in 2 patients. Patho-
physiologically, this increase is difficult to explain. Never-
theless, the authors concluded that TMLR causes sympa-
thetic myocardial denervation without affecting perfusion.
Compared with the study of Al-Sheikh and coworkers,13
our design has several advantages. First, only one of our
patients had diabetes (vs 5 of 8 in Al-Sheikh and coworkers’
study), which minimizes the possible interference of neu-
ropathy with the scintigraphic results. In this patient (with
Figure 2. Venn diagram of segments treated with TMLR (dark
gray) preoperatively showing a reversible perfusion defect (light
gray) and a positive myocardial denervation score (white). As an
example, 28 segments preoperatively showed a reversible perfu-
sion defect, were treated with TMLR, and postoperatively did not
show denervation. Of the 14 segments that preoperatively showed
a reversible perfusion defect, were not treated, and did not show
denervation, 5 were midseptal segments, which cannot be
treated. Consequently, a total of 58 reversible perfusion defect
segments were eligible for TMLR.
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type II diabetes) no clinical signs of neuropathy were iden-
tified. Furthermore, even when excluding this patient from
analyses, the observed denervation in the remaining 7 pa-
tients was still highly significant (P  .0002). Second, we
assessed denervation at 1, 4, 9, and 16 months and found
clinical benefit and denervation at all follow-up times.
Given the controversy concerning the long-term efficacy of
TMLR, this is an important finding, even though it was
Figure 3. Bull’s-eye representation of myocardial innervation and perfusion in a representative case (patient 4)
showing denervation after TMLR. Eight months postoperative 123I-MIBG scintigraphy (B) shows, compared with
preoperative values (A), anterolaterally decreased uptake corresponding with the TMLR-treated area. C displays
the difference between preoperative and postoperative 123I-MIBG scintigraphy compatible with denervation in the
TMLR-treated area. No improvement in ischemia was observed in the TMLR-treated area 12 months postoperatively
(E) compared with preoperative values (D, both panels displayed as reversibility plots). The level of radioactivity
(A and B) and difference (C, D, and E) is encoded from low (black) through medium (yellow) to high (white). F shows
the 18-segment model of the left ventricle: 4 basal, 6 midventricular, 6 preapical, and 2 apical segments. The gray
segments, representing the membranous part of the interventricular septum, were excluded in all analyses.
*Segments never treated with TMLR. MPS, Myocardial perfusion scintigraphy; ANT, anterior; LAT, lateral; INF,
inferior; SEPT, septal.
TABLE 3. Results of 123I-MIBG SPECT and myocardial perfusion scintigraphy
Patient no.
123I-MIBG SPECT scintigraphy Myocardial perfusion scintigraphy
Preoperative
SS
Postoperative
SS SMDS
Preoperative
SDS 3 mo SDS 12 mo SDS
1 19 26 7 6 9 8
2 19 28 9 28 16 23
3 12 22 10 39 26 14
4 14 26 12 14 21 22
5 8 24 16 6 12 6
6 21 30 9 9 7 11
7 18 24 6 3 6 6
8 7 16 9 8 3 3
Mean  SD 14.8 5.3 24.5 4.2* 9.8 3.1 14.1 12.7 12.5 7.9 11.6 7.5
SS, Summed score; SMDS, summed myocardial denevation score; SDS, summed difference score.
*P  .00005 compared with preoperative value (and P  .0002 when excluding patient 6, who had diabetes mellitus type II).
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investigated in only a few patients. Third, this study com-
pares for each of 18 segments in the areas that showed
denervation versus the TMLR-treated areas. Of 74 TMLR-
treated segments, 33 (45%) segments showed denervation.
Apparently, not every transmyocardial laser perforation de-
stroys nerves or at least not enough to significantly decrease
MIBG uptake. However, because all patients postopera-
tively showed decreased MIBG uptake and all experienced
significant clinical improvement, we hypothesize that this
incomplete denervation of treated segments is sufficient to
relieve angina. Inversely, 33 (66%) of 50 denervated seg-
ments were treated. Of the remaining 17 nontreated seg-
ments, 10 were preapical or apical segments. As also pos-
tulated by Al-Sheikh and coworkers,13 denervation of
nontreated (pre-) apical segments might result from proxi-
mal (upstream) lesions that interrupt sympathetic nerve fi-
bers that connect with the apex. Consequently, we con-
cluded that in 86% (43/50) of all segments that showed
denervation, decreased MIBG uptake could be attributed to
TMLR. Why denervation occurred in the remaining 7 non-
treated segments is unclear. Although myocardial ischemia
might play a role in cardiac neuronal damage,30 only 3 of
the 7 remaining nontreated segments showed ischemia,
leaving unexplained denervation in 4 segments. These de-
nervated segments were distributed over 3 patients (with 1
month’s follow-up): 1 segment showed a denervation score
of 2, and 3 segments showed denervation scores of only 1.
Given our method of recording the treated area, it is entirely
possible that a shift or uncertainty of some centimeters
might occur in the TMLR polar plot compared with in the
scintigraphic scans. As a result, this could have led to minor
errors in our analysis, and this might explain some of the
inconsistencies. We have considered 3 other possible expla-
nations for the denervation in the 4 segments: (1) sponta-
neous denervation, (2) thoracotomy-related denervation, or
(3) a variation in observed MIBG uptake. However, we
rejected them because (1) in our opinion spontaneous de-
nervation is unlikely given the short time span used in this
study, (2) there is no theoretic basis for decreased MIBG
uptake solely induced by the thoracotomy, and (3) any
uptake-related variation would by expected to be 2 sided.
Because none of the investigated segments showed in-
creased innervation, this last explanation also seems un-
likely.
Finally, we performed both Holmium:YAG and excimer
TMLR. Despite differences in laser-tissue interaction,10 no
laser-specific differences in denervation or myocardial dam-
age (CK-MB) were observed. However, for this compari-
son, groups were too small to draw definite conclusions. If
denervation would be the only working mechanism of
TMLR, it is highly likely that the antianginal effect would
decrease with reinnervation of the myocardium. Similarly, a
return of anginal complaints is observed after reinnervation
of transplanted hearts. However, a sustained relief might be
induced if the initial TMLR-induced anginal relief caused
by denervation results in, for instance, a change in lifestyle
with increased exercise (inducing increased capillary shear
rates and arteriogenesis).
Conclusion
In all patients undergoing Holmium:YAG and excimer
TMLR, evidence of denervation was found, whereas no
improvement was seen in perfusion. The coinciding im-
provement in angina and QOL suggests that myocardial
denervation plays an important role in the efficacy of
TMLR. Consequently, further research is indicated to in-
vestigate whether other methods to induce myocardial de-
nervation might be at least as effective, simpler, and cheaper
in relieving angina and improving QOL in patients with
severe refractory angina.
We thank Anne Oosterdijk and Iwan Dobbe for their technical
support.
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